Consio | $3,300,000 | (Jan 27, 2026)
Orbital(US) | $60,000,000 | (Jan 27, 2026)
Inferact | $150,000,000 | (Jan 27, 2026)
Evozyne
United States
- Chicago, IL
- 28/09/2023
- Series B
- $81,000,000
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.
- Industry Biotechnology
- Website https://www.evozyne.com/
- LinkedIn https://www.linkedin.com/company/evozyne/about/
Related People
Mike GamsonFounder
United States -
Greater Chicago Area
I'm passionate about leading teams to pursue inspiring goals. I love working with intellectually curious people who can do anything, but show up everyday with humility and a drive to be better than they were yesterday. I believe that driving results matters as does taking the time in life to stop to smell the roses. I aspire to be a great colleague and I hope to be a student of new things forever.
Visitt | $22,000,000 | (Jan 27, 2026)
Cashmere(US) | $5,000,000 | (Jan 27, 2026)
Barnwell Bio | $6,000,000 | (Jan 27, 2026)
Mine(US) | $14,000,000 | (Jan 27, 2026)
Lucend | $3,300,000 | (Jan 27, 2026)
Standard Nuclear | $140,000,000 | (Jan 27, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)